Prakt. lékáren. 2022; 18(4): 208-213 | DOI: 10.36290/lek.2022.044

Current trends in pharmacotherapy of metabolic syndrome

Lenka Ťupová, Aleš Šorf

Katedra sociální a klinické farmacie, Farmaceutická fakulta UK v Hradci Králové, Hradec Králové

Metabolic syndrome (MS) can be defined as a cluster of risk factors that significantly predict the development of life-threatening cardiovascular complications. The cornerstones of MS management are identification of patients in early stages and their positive motivation to change the lifestyle which is critical to properly compensate individual components of MS. Pharmacists also play a key role in the management of MS. When regimen changes are found insufficient or when the disease state is decompensated, the pharmacological treatment is indicated. Alongside the gold standard medicines such as ACE inhibitors, statins or metformin, new modern drugs come to the fore and their introduction is the aim of this article. These modern drugs often affect multiple components of MS at the same time including abdominal obesity which has recently been recognized as a full-fledged diagnosis. Furthermore, emphasis is being put on choosing the advantageous combinations of drugs so that their effect is maximized, and their adverse effects are prevented, e.g. in case of potential weight gain or cardiovascular disorders.

Keywords: metabolic syndrome, abdominal obesity, insulin resistance, pharmacotherapy.

Accepted: December 1, 2022; Published: December 15, 2022  Show citation